Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
Background: Cystic fibrosis (CF) is associated with worsening of depression and anxiety symptoms. Elexacaftor/tezacaftor/ivacaftor (Trikafta®), a cystic fibrosis transmembrane regulator (CFTR) modulator approved in 2019, significantly improves lung function, decreases pulmonary exacerbations, and im...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publishing
2022-12-01
|
| シリーズ: | Therapeutic Advances in Respiratory Disease |
| オンライン･アクセス: | https://doi.org/10.1177/17534666221144211 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|